Photocure (OSE: PHO) is committed to driving progress in uro-oncology precision diagnostics, delivering meaningful advanc We tweet about #bladdercancer #cancer.
Oslo, Norge
Joined January 2014
- Tweets598
- Following289
- Followers992
- Likes131
Photocure today reported Hexvix®/Cysview® revenues of NOK 134.2 million in the third quarter of 2026 (Q3 2025: NOK 134.1 million), and Adjusted EBITDA of NOK 18.5 million (Q3 2025: NOK 18.9 million). Read more: photocure.com/news/photocure…
#LondonLifeScienceWeek: Photocure leadership will be attending Jefferies Global Healthcare Conference on Nov 16-18 and organizing individual IR & BD meetings. Feel free to reach out if you would like to meet with management.
D. Schneider, A. Neijber, J. Healy, P. Shah, R. Kitchen
The Photocure team will be presenting at the upcoming Pareto Securities’ Swiss Nordic Bio Conference on October 1 in Zurich.
swissnordicbio.com/
#precisiondiagnostics #urooncology #bladdercancer
Join the EAU/ESU UROwebinar supported by Photocure: The AI-augmented urologist — A realistic future in bladder cancer? 22 Sept 2026, 18:30 CEST. Healthcare professionals can register: webinars.uroweb.org/EAU/webi…
#BladderCancer #Urology #AI #ArtificialIntelligence #MedicalEducation
With innovative solutions for bladder cancer diagnosis and a clear focus on improving patient care, Photocure will be attending the Congress of the German Society of Urology (DGU) in Düsseldorf from September 16-19, 2026.
We look forward to meeting you!
#DGU2026 #Urooncology
ALT Photocure to participate in the DGU 2026 Congress
Inspiring conversations at the Pareto Securities’ Healthcare Conference! Our CEO Dan Schneider participated in the panel, discussing AI strategy and industry transformation, US pricing reform and commercialization, as well as current regulatory developments.
#precisiondiagnostics
Photocure today reported Hexvix®/Cysview® revenues of NOK 140.0 million in Q2 2026 (Q2 2025: NOK 135.6 million), and an adjusted EBITDA of NOK 27.2 million (Q2 2025: NOK 27.0 million). Read more: photocure.com/news/photocure…
Photocure ASA to acquire Vesica Health a U.S. based precision diagnostics company advancing AssureMDx, a urine based molecular test: photocure.com/news/photocure…
#bladdercancer #precisionmedicine #precisiondiagnostics #urooncology #biomarker
ALT Photocure acquires Vesica Health
#Bladdercancerawarenessmonth! For the 13th year, Photocure is once again a proud sponsor of the @BladderCancerUS 's Walks to End #Bladdercancer.
This month, our team participated - or will participate - in 13 different local walks throughout the U.S.
Congratulations to BCAN!
ALT Photocure colleagues at BCAN's walks to end bladder cancer 2026 in the U.S.
In Sweden, Photocure supports a Patient Association information event from Blåscancer Förbundet during #bladdercancerawarenessmonth.
The meeting is on 27 May in Stockholm, 6.00 pm – 7.45 pm.
#bladdercanceraware #medicaleducation #urooncology
Photocure supports the digital #bladdercancer awareness campaign of the Urologische Stiftung Gesundheit: info for patients on bladder cancer symptoms, risk factors and myths, airing throughout 2026.
#bladdercanceraware #bladdercancerawarenessmonth #medicaleducation #urooncology
ALT “Blood in the urine can be a sign of bladder cancer. Make the www.urocheck.de”
ALT “Misconception: bladder cancer is a men's disease. One in four affected individuals is a woman.”
ALT “Blood in the urine is never normal.”
Photocure today reported Hexvix®/Cysview® revenues of NOK 139.0 million in Q1 2026 (Q1 2025: NOK 125.3 million), and an adjusted EBITDA of NOK 15.3 million (Q1 2025: NOK 9.7 million).
Read more: photocure.com/news/photocure…
Introducing Photocure's 2025 Annual Report and Sustainability Statement. Read more about our commitment to bladder cancer diagnostics, where precision matters. cms.photocure.com/uploads/Ph…
#annualreport #sustainability #ESG #urooncology #bladdercancer
Photocure is participating in the EAU Congress in London, UK!
Come meet our team at Booth F21.
#EAU26 #BladderCancer #LeadingChange
ALT Photocure at the European Association of Urology Annual Meeting 2026
Photocure today reported Hexvix®/Cysview® revenues of NOK 135.1 million in the Q4 2025 (Q4 2024: NOK 128.6 million), and a commercial EBITDA of NOK 8.4 million (Q4 2024: NOK 3.9 million). Read more: photocure.com/news/photocure…
New UROwebinar: "Bladder preservation – A changing paradigm in treatment"
Organised by the European School of Urology with the support of Photocure: 10 Feb 2026, 18:30-19:30 CET. HCPs register here: webinars.uroweb.org/login
Speakers: P. Gontero, L. S. Mertens, M. Rouprêt
Thank you for your continued support. We certainly had our share of exciting developments in 2025 at Photocure and are looking forward to a fantastic 2026! We wish you all a happy, healthy and successful New Year!
photocure.com/news
ALT Photocure Team wishing you a Happy New Year 2026
Attending the Society of Urologic Oncology 2025 Annual Meeting (SUO) December 2-5, 2025, in Phoenix, Arizona? Meet our teams at the joint Photocure - KARL STORZ booth. Location: Sheraton Phoenix Downtown.
#SUO2025 #bladdercancer #urooncology
Photocure is attending the International Conference on Endourology (ICE25) in Rome, 27–29 November 2025.
We look forward to meeting you at booth N° 11.
#ICE25 #Urology #BladderCancer
Learn more about health economics, key modelling tools, and how insights can impact bladder cancer care. Our experts discuss their latest research.
Watch the video now.
photocure.com/our-perspectiv…
#BladderCancer #healtheconomics #urology
